Results about: patients
As of November, Núria López-Bigas, winner of the 2016 Banco Sabadell Foundation Prize for Biomedical Research, will join IRB Barcelona to continue her research on cancer using computational biology.
The Institute has also recruited Croatian scientist Fran Supek, who will launch his laboratory in 2017.
The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
Centres of excellence in biomedical research in Barcelona offer five fellowships as part of the new edition of the predoctoral programme in biomedicine for physicians, PhD4MD.
The initiative allows physicians to embark on a three-year research project on topics such as cancer, chronic obstructive pulmonary disease, fertility, and AIDS vaccines.
Thanks to the collaboration among research centres, the studies will address two distinct facets of biomedicine: basic molecular research and more applied clinical work.